Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- New AbbVie Japan Chief Says Generics Making Room for Innovation
July 29, 2015
- Kyowa Kirin Kicks Off Japan PIII Study on Benralizumab for COPD
July 29, 2015
- EMA Accepts Applications for Opdivo for Non-Squamous NSCLC and in Combination with Yervoy for Advanced Melanoma: BMS
July 29, 2015
- Chugai’s Sales Reps to Provide ADR Information on the Spot from Mid-2016
July 29, 2015
- MSD Applies for 9-Valent HPV Vaccine
July 29, 2015
- Ixazomib Granted Accelerated Assessment in EU: Takeda
July 29, 2015
- Takeda, DNDi Partner for Development of Visceral Leishmaniasis Treatment
July 29, 2015
- Carfilzomib Approved for Combination Use in US: Ono
July 29, 2015
- Delving into Securities Filings - 1: Average Salary of 25 Makers Up 4.9% in 5 Years, Generic Players Close in on Top-Tier Firms
July 29, 2015
- Eisai Files for Regulatory Approval of Perampanel in Japan
July 28, 2015
- Japan Drug Makers Should Consider Mergers, Other Deals to Survive: Chugai Chief
July 27, 2015
- Toho to Narrow Down Recommended Drug Makers, Will Need to Devise Specific Marketing Policy for Generics: Pres. Edahiro
July 27, 2015
- Fujifilm, Kyowa Kirin JV to Develop Avastin Biosimilar with AZ
July 27, 2015
- Kyowa Kirin Ups Earnings Outlook on Nesp, G-Lasta
July 27, 2015
- Sumitomo Dainippon, Kyoto Univ., Hitachi to Collaborate on Regenerative Medicine for Parkinson’s Disease Utilizing iPS Cells
July 27, 2015
- Chugai Revenues Up 8.2% on Cancer Drugs, Actemra
July 24, 2015
- Toho to Differentiate Itself through Customer Support Rather than Prices: Pres.
July 24, 2015
- Astellas, AIST Partner Up for Joint Research for IT Drug-Discovery Technologies
July 24, 2015
- Kyowa Kirin to File for Regulatory Approval of Psoriasis Treatment Brodalumab
July 24, 2015
- EU Approves Opdivo for Squamous NSCLC: BMS
July 23, 2015
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…